Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.

Wedbush raised the firm’s price target on Tourmaline Bio (TRML) to $43 from $42 and keeps an Outperform rating on the shares. All key ...

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total ...

Tourmaline Oil Corp. closed 6.2% below its 52-week high of C$70.83, which the company achieved on February 21st.

My last article some years back noted that Charlie Lake had a lot of profit potential, and Tourmaline was there first. As the slide above shows, Charlie Lake has one of the best profit potentials ...

The firm no longer sees an actionable short with the shares now close to its price tar NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage ...

The market expects Tourmaline Oil Corp. (TRMLF) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known ...

Fintel reports that on February 24, 2025, LifeSci Capital initiated coverage of Tourmaline Bio (NasdaqGS:TRML) with a Outperform recommendation. Analyst Price Forecast Suggests 376.60% Upside As of ...

Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...

Tourmaline Oil remains Canada’s largest natural gas producer and continues to reward investors through both regular and special dividends. In its most recent earnings, Tourmaline reported revenue of ...

Product on Amazon: 6-in-1 Curling Iron, a versatile set that includes six interchangeable ceramic barrels, adjustable ...